Such CALR mutations have been identified in approximately 25–30% of ET cases (preferentially type I mutations) and 20–30% of PMF cases (preferentially type II mutations) and are a diagnostic criterion for both of these diseases [30]. This evidence concerns the gene CALR and essential thrombocythemia.